ArticleDiscover oncology2025
Enhanced magnetic resonance imaging-based radiomics predicts CD40LG expression and survival in high-grade gliomas: a retrospective study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to assess the prognostic significance of CD40LG and a related radiomics model in high-grade gliomas.
methodsThis retrospective cohort study utilized data from TCGA (n = 298) and TCIA (n = 89) following STROBE guidelines. From The Cancer Genome Atlas (TCGA), HGGs with genomic and clinical data were analyzed to establish CD40LG's prognostic value through Kaplan-Meier survival analysis and multivariate Cox regression. A radiomic model, based on TCGA data and matched MRI T1 images from The Cancer Imaging Archive (TCIA), was built to predict CD40LG levels. Radiomic features were extracted via PyRadiomics, filtered by 1000-repeat LASSO regression, and validated through 5-fold cross-validation. An independent cohort (n = 182) tested the model's prognostic utility. Subsequently, a prognostic model and nomogram were developed.
resultsKaplan-Meier curves indicated a significant association between CD40LG expression and overall survival. CD40LG emerged as a crucial risk factor in both univariate and multivariate analyses. Immune cell infiltration analyses highlighted CD40LG's connection to the tumor immune microenvironment. A radiomic model, constructed using LASSO regression and five features, successfully predicted CD40LG expression pre-surgery. Combining the model's Rad-scores with clinical data, we created an effective prognostic model.
conclusionsCD40LG expression correlates with high-grade glioma prognosis. Our MRI-based radiomic signature predicted CD40LG expression and prognosis, offering potential guidance for treatment decisions and future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.